Sandbox Reserved 1058
From Proteopedia
(Difference between revisions)
| Line 18: | Line 18: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
[[Image:TCA_Cycle.png|500 px|left|thumb|'''Figure 1. Citric Acid Cycle with Glyoxylate Shunt Pathway.''' In several bacterial species, there is a carbon conserving gloxylate shunt pathway that converts isocitrate to malate in two steps instead of the usual five steps.]] | [[Image:TCA_Cycle.png|500 px|left|thumb|'''Figure 1. Citric Acid Cycle with Glyoxylate Shunt Pathway.''' In several bacterial species, there is a carbon conserving gloxylate shunt pathway that converts isocitrate to malate in two steps instead of the usual five steps.]] | ||
| - | + | [[Image:Active_Site_Hydrogen_Bonding.png|250 px|left|thumb|'''Figure 3. Active site residues hydrogen bound to a cofactor and the products of the catalyzed isocitrate reaction.''' Glyoxylate is shown in blue, succinate is shown in green, and the Mg<sup>2+</sup> cofactor is shown in yellow.]] | |
==Disease Association== | ==Disease Association== | ||
===Clinical Implications=== | ===Clinical Implications=== | ||
''Mycobacterium tuberculosis'' is a respiratory infection that causes numerous fatalities throughout the world. It lives in organisms and feeds off of host cells, which indicate a variety of lipases exist within ''M. tuberculosis''. Current drugs that are on the market now target a small number of bacterial processes like cell wall formation and chromosomal replication. Although several antibiotics exist, all of them target these same mechanisms of inhibition. These commonalities have led to the prevalence of different multi-drug resistant (MDR) tuberculosis strains. Due to the high level of resistance, finding a lasting treatment for MDR TB infections has become very problematic. Studies into new mechanisms of inhibition will be crucial to prevent widespread outbreaks. | ''Mycobacterium tuberculosis'' is a respiratory infection that causes numerous fatalities throughout the world. It lives in organisms and feeds off of host cells, which indicate a variety of lipases exist within ''M. tuberculosis''. Current drugs that are on the market now target a small number of bacterial processes like cell wall formation and chromosomal replication. Although several antibiotics exist, all of them target these same mechanisms of inhibition. These commonalities have led to the prevalence of different multi-drug resistant (MDR) tuberculosis strains. Due to the high level of resistance, finding a lasting treatment for MDR TB infections has become very problematic. Studies into new mechanisms of inhibition will be crucial to prevent widespread outbreaks. | ||
Isocitrate lyase plays a key role in survival of ''M. tuberculosis'' by sustaining intracellular infections in inflammatory respiratory macrophages. Used in the citric acid cycle, isocitrate lyase is the first enzyme catalyzing the carbon conserving glyoxylate pathway. This glyoxylate pathway has not been observed in mammals and thus presents a unique drug target to solely attack TB infections. | Isocitrate lyase plays a key role in survival of ''M. tuberculosis'' by sustaining intracellular infections in inflammatory respiratory macrophages. Used in the citric acid cycle, isocitrate lyase is the first enzyme catalyzing the carbon conserving glyoxylate pathway. This glyoxylate pathway has not been observed in mammals and thus presents a unique drug target to solely attack TB infections. | ||
| - | |||
| - | ===Ligand Bound=== | ||
| - | [[Image:Active_Site_Hydrogen_Bonding.png|250 px|center|thumb|'''Figure 3. Active site residues hydrogen bound to a cofactor and the products of the catalyzed isocitrate reaction.''' Glyoxylate is shown in blue, succinate is shown in green, and the Mg<sup>2+</sup> cofactor is shown in yellow.]] | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
Revision as of 18:00, 7 April 2015
Isocitrate Lyase from Mycobacterium tuberculosis
| |||||||||||
